Assessment of genotoxicity in rats treated with the antidiabetic agent, pioglitazone

Environmental and Molecular Mutagenesis

Volumn 49, Issue 3, 2008, Pages 185-191

  Bedir, Abdulkerim ^a   Aliyazicioglu, Yuksel ^a   Bilgici, Birsen ^a   Yurdakul, Zafer ^a   Uysal, Mehmet ^a   Suvaci, Duygu Erol ^a   Okuyucu, Ali ^a   Kahraman, Hakki ^a   Hökelek, Murat ^a   Alvur, Muhlise ^a  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

Author keywords

Comet assay; Genotoxicity; Pioglitazone; Single cell gel electrophoresis

Indexed keywords

DNA FORMAMIDOPYRIMIDINE GLYCOSYLASE; ENDONUCLEASE; PIOGLITAZONE; PURINE; PYRIMIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD; CELL NUCLEUS; CELL VIABILITY; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DOSE RESPONSE; DRUG LABELING; EXPERIMENTAL RAT; GENOTOXICITY; LIVER CELL; LYMPHOCYTE; MALE; NONHUMAN; OXIDATION; OXIDATIVE STRESS; RAT; STATISTICAL SIGNIFICANCE;

ANIMALS; COMET ASSAY; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPATOCYTES; HYPOGLYCEMIC AGENTS; LYMPHOCYTES; MALE; MUTAGENICITY TESTS; MUTAGENS; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES;

ANIMALIA; RATTUS;

EID: 41849092666     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20365     Document Type: Article

References (41)

1. Angelis KJ, Dusinská M, Collins AR. 1999. Single cell gel electrophoresis: Detection of DNA damage at different levels of sensitivity. Electrophoresis 20:2133-2138.
2. Balfour JA, Plosker GL. 1999. Rosiglitazone. Drugs 57:921-930.
3. Bedir A, Aliyazicioglu Y, Kahraman H, Yurdakul Z, Uysal M, Suvaci DE, Okuyucu A, Hökelek M, Alvur M. 2006. Genotoxicity in rats treated with the antidiabetic agent, Rosiglitazone. Environ Mol Mutagen 47:718-724.
4. Collins AR. 1999. Oxidative DNA damage, antioxidants, and cancer. Bioessays 21:238-246.
5. Collins AR. 2004. The comet assay for DNA damage and repair: Principles, applications and limitations. Mol Biotechnol 26:249-261.
6. Collins AR, Raslova K, Somorovska M, Petrovska H, Ondrusova A, Vohnout B, Fabry R, Dusinska M. 1998. DNA damage in diabetes: Correlation with clinical marker. Free Radic Biol Med 25:373-377.
7. Day C. 1999. Thiazolidinediones: A new class of antidiabetic drugs. Diabet Med 16:179-192.
8. Dandona P, Thusu K, Cook S, Snyder B, Makowski J, Armstrong D, Nicotera T. 1996. Oxidative damage to DNA in diabetes mellitus. Lancet 347:444-445.
9. Delerive P, Fruchart JC, Staels B. 2001. Peroxisome proliferator- activated receptors in inflammation control. J Endocrinol 169:453-459.
10. Feinstein DL, Spagnolo A, Akar C, Weinberg G, Murphy P, Gavrilyuk V, Dello RC. 2005. Receptor-Independent actions of PPAR Thiazolidinedione agonists: Is mitochondrial function the key? Biochem Pharmacol 70:177-188.
11. Froguel P, Velho G. 2001. Genetic determinants of type 2 diabetes. Recent Prog Horm Res 56:91-105.
12. Furukawa M, Nishimura M, Ogino D, Chiba R, Ikai I, Ueda N, Naito S, Kuribayashi S, Moustafa MA, Uchida T, Sawada H, Kamataki T, Funae Y, Fukumoto M. 2004. Cytochrome P450 gene expression levels in peripheral blood mononuclear cells in comparison with the liver. Cancer Sci 95:520-529.
13. Gillies PS, Dunn CJ. 2000. Pioglitazone. Drugs 60:333-343.
14. Grommes C, Landreth GE, Heneka MT. 2004. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol 5:419-429.
15. Grossman SL, Lessem J. 1997. Mechanism and clinical effects of thiazolidinediones. Exp Opin Invest Drugs 6:1025-1040.
16. Hartmann A, Agurell E, Beevers C, Brendler-Schwaab S, Burlinson B, Clay P, Collins A, Smith A, Speit G, Thybaud V, Tice RR. 2003. Recommendations for conducting the in vivo alkaline Comet assay. 4th International Comet Assay Workshop. Mutagenesis 18:45-51.
17. Kahn CR, Chen L, Cohen SE. 2000. Unraveling the mechanism of action of thiazolidinediones. J Clin Invest 106:1305-1307.
18. Kameda N, Okuya S, Oka Y. 2000. Rosiglitazone (BRL-49653). Nippon Rinsho 58:401-404.
19. Kassahun K, Pearson PG, Tang W, McIntosh I, Leung K, Elmore, Dean D, Wang R, Doss G, Baillie TA. 2001. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidine ring scission. Chem Res Toxicol 14:62-70.
20. Kawakami S, Arai G, Hayashi T, Fujii Y, Xia G, Kageyama Y, Kihara K. 2002. PPARgamma ligands suppress proliferation of human urothelial basal cells in vitro. J Cell Physiol 191:310-319.
21. Kohlroser J, Mathai J, Reichheld J, Banner BF, Bonkovsky HL. 2000. Hepatotoxicity due to troglitazone: Report of two cases and review of adverse events reported to United States Food and Drug Administration. Am J Gastroenterol 95:272-276.
22. Konca K, Lankoff A, Banasik A, Lisowska H, Kuszewski T, Gozdz S, Koza Z, Wojcik A. 2003. A cross-platform public domain PC image-analysis program for the comet assay. Mutat Res 534:15-20.
23. Lee RF, Steinert S. 2003. Use of the single cell gel electrophoresis/ Comet assay for detecting DNA damage in aquatic (marine and freshwater) animals. Mutat Res 544:43-66.
24. Levovitz HE, Kreider M, Freed MI. 2002. Evaluation of liver function in type 2 diabetic patients during clinical trials: Evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 25:815-821.
25. Maeda K. 2001. Hepatocellular injury in a patient receiving pioglitazone. Ann Intern Med 135:306.
26. May L, Lefkowitch J, Kram M, Rubin D. 2002. Mixed hepatocellular- cholestatic liver injury after pioglitazone therapy. Ann Intern Med 136:449-452.
27. Marcy TR, Britton ML, Blevins SM. 2004. Second-generation thiazolidinediones and hepatotoxicity. Ann Pharmacother 38:1419-1423.
28. Moller P. 2006. The alkaline comet assay: Towards validation in biomonitoring of DNA damaging exposures. Basic Clin Pharmacol Toxicol 98:336-345.
29. Narayanan PK, Hart T, Elcock F, Zhang C, Hahn L, McFarland D, Schwartz L, Morgan DG, Bugelski P. 2003. Troglitazone-induced intracellular oxidative stress in rat hepatoma cells: A flow cytometric assessment. Cytometry A 52:28-35.
30. Pan HZ, Chang D, Feng LG, Xu FJ, Kuang HY, Lu MJ. 2007. Oxidative damage to DNA and its relationship with diabetic complications. Biomed Environ Sci 20:160-163.
31. Perez-Ortiz JM, Tranque P, Burgos M, Vaquero CF, Llopis J. 2007. Glitazones induce astroglioma cell death by releasing reactive oxygen species from mitochondria: Modulation of cytotoxicity by nitric oxide. Mol Pharmacol 72:407-417.
32. Plosker GL, Faulds D. 1999. Troglitazone. A review of its use in the management of type 2 diabetes mellitus. Drugs 57:409-438.
33. Saiki M, Hatta Y, Yamazaki T, Itoh T, Enomoto Y, Takeuchi J, Sawada U, Aizawa S, Horie T. 2006. Pioglitazone inhibits the growth of human leukemia cell lines and primary leukemia cells while sparing normal hematopoietic stem cells. Int J Oncol 29:437-443.
34. Saltiel AR, Olefsky JM. 1996. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669.
35. Sheen AJ. 1997. Drug treatment of non-insulin dependent diabetes mellitus in the 1990s: Achievements and future developments. Drugs 54:355-368.
36. Singh NP, McCoy MT, Tice RR, Schneider EL. 1988. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 175:184-191.
37. Spencer CM, Markham A. 1997. Troglitazone. Drugs 54:89-101.
38. Spiegelman BM. 1998. PPAR-gamma adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507-514.
39. Takanaga H, Kunimoto M, Adachi T, Tohyama C, Aoki Y. 2001. Inhibitory effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on cAMP-induced differentiation of rat C6 glial cell line. J Neurosci Res 64:402-409.
40. Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, Miyamae Y, Rojas E, Ryu JC, Sasaki YF. 2000. Single cell gel/comet assay: Guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 35:206-221.
41. Watkins PB, Whitcomb RW. 1998. Hepatic dysfunction associated with troglitazone (Letter). N Engl J Med 338:916-917.